Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) CBCRisk model to determine the risk of contralateral breast cancer in sporadic b...
Journal Information
Vol. 99. Issue 10.
Pages 724-729 (December 2021)
Share
Share
Download PDF
More article options
ePub
Visits
1
Vol. 99. Issue 10.
Pages 724-729 (December 2021)
Original article
CBCRisk model to determine the risk of contralateral breast cancer in sporadic breast cancer
Modelo CBCRisk para determinar el riesgo de cáncer de mama contralateral en el cáncer de mama esporádico
Visits
...
María Domingo Bretóna,
Corresponding author
mdominbre@gmail.com

Corresponding author.
, Marta Allué Cabañuza, Néstor Castán Villanuevaa, María Dolores Arribas del Amob, Ismael Gil Romeab, Antonio Güemes Sánchezb
a Servicio de Cirugía General, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
b Servicio de Cirugía General, Unidad de Mama, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Demographic and clinical-pathological data.
Table 2. 5-year CBCRisk and anatomic-pathological findings in CPM specimens.
Table 3. Analysis of predictive factors of CBC and/or MHRL.
Show moreShow less
Figures (1)
Abstract
Introduction

The great majority of breast cancer (BC) cases are diagnosed in women who have no known family history of the disease and are not carriers of any risk mutation. During the past few decades an increase in the number of contralateral prophylactic mastectomy (CPM) has been produced in these patients. The CBCRisk model calculates the absolute risk of suffering from contralateral breast cancer (CBC); thus, it can be used to counselling patients with sporadic breast cancer.

Method

An observational, retrospective study including sporadic breast cancer patients treated with contralateral prophylactic mastectomy has been conducted between 2017 and 2019. A descriptive and comparative study with one variation of logistic regression has been carried out in order to identify predictive factors of occult tumors (OT) and medium/high risk damage (MHRD). Evaluation of the CBCRisk model published in 2017 and different limit values for the CPM recommendation.

Results

42 patients were selected. Incidence of MHRD and OT was lower than that described in the literatura (9.52%MHRD, 2.38%OT). None of the evaluated variables reached statistical significance for predicting injuries. The average value of CBCRisk 5 years ahead found in patients with pathological findings was 2.08 (DE 0.97), higher than the average value of the whole group (1.87 ± 0.91) and the subgroup without pathological findings (1.84 ± 0.91). Only values >3 for CBCRisk were considered statistically significant (P = .04) for the prediction of histological lesions.

Conclusion

Patients with sporadic breast cancer should be adequately informed about the estimated risks and benefits of undergoing a contralateral prophylactic mastectomy. The CBCRisk may be useful for the counseling of these patients, but it requires validation in larger and prospective cohorts.

Keywords:
Breast cancer
Risk-reducing mastectomy
Contralateral prophylactic mastectomy
Risk assessment
CBCRisk
Resumen
Introducción

La mayoría de los cánceres de mama (CM) se diagnostican en mujeres sin antecedentes familiares y no portadoras de mutaciones de riesgo. En las últimas décadas se ha producido un aumento de mastectomías profilácticas contralaterales (MPC) en estas pacientes. El CBCRisk es un modelo que calcula el riesgo absoluto de cáncer de mama contralateral (CMC) y pretende servir para el asesoramiento de pacientes con CM esporádico sobre la MPC.

Método

Análisis observacional retrospectivo de pacientes con un cáncer de mama esporádico sometidas a MPC durante 2017−2019. Análisis descriptivo, comparativo y de regresión logística univariante para identificar factores predictivos de LMAR y/o CMC oculto. Evaluación del modelo CBCRisk publicado en 2017 y distintos valores límite para la recomendación de MPC.

Resultados

Se seleccionaron 42 pacientes. Incidencia de LMAR y CO menor que la descrita en la literatura (9.52%LMAR, 2,38%CO). Ninguna de las variables evaluadas alcanzó significación estadística para la predicción de lesiones. El valor de CBCRisk a 5 años medio en pacientes con hallazgos patológicos fue de 2.08(DE 0.97), superior al CBCRisk medio del conjunto (1.87 ± 0.91) y del subgrupo de MPC sin hallazgos patológicos (1.84 ± 0.91). Sólo el CBCRisk>3 resultó significativo (P = .04) para la predicción de hallazgos patológicos.

Conclusión

Las pacientes con CM esporádico deben ser adecuadamente informadas de los riesgos y beneficios estimados de la MPC. El CBCRisk puede ser útil para el asesoramiento de estas pacientes, pero precisa validación en cohortes más amplias y prospectivas.

Palabras clave:
Cáncer de mama
Mastectomía reductora de riesgo
Mastectomía profiláctica contralateral
Riesgo
CBCRisk

Article

These are the options to access the full texts of the publication Cirugía Española (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Cirugía Española (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos